{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:23:07Z","timestamp":1780590187635,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC) and several antiviral agents are available for the treatment of chronic HCV infection. However, the impact of antiviral therapy on the long-term outcomes of HCV-related HCC patients remains inconclusive. We aimed to examine the impact of antiviral therapy on the long-term outcomes of HCV-related HCC patients. We conducted a systematic review using PRISMA guidelines to identify trials and English-language literature from PubMed, Ovid MEDLINE, Scopus and the Cochrane Library database till August 2014. Randomized trials of antiviral treatments examining the effects of antiviral therapy on CHC patients and HCV-related HCC patients were screened and selected. We identified 6 trials evaluated the effectiveness of interferon (IFN)-alfa treatment, 3 studies examined pegylated interferon-alfa treatment and 2 studies examined IFN-beta treatment. IFN-based therapy may decrease HCC incidence in HCV cirrhotic patients after a &gt;5-year follow-up, improve liver reserve, decrease HCC recurrence rate and increase survival rate in HCV-related HCC patients after curative HCC therapy. In conclusion, IFN-based therapy is beneficial and may be recommended in the management of HCV-related HCC patients who are IFN eligible.<\/jats:p>","DOI":"10.1038\/srep09954","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T12:29:01Z","timestamp":1431433741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma"],"prefix":"10.1038","volume":"5","author":[{"given":"Ching-Sheng","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Chen","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Hsienhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"BFsrep09954_CR1","doi-asserted-by":"publisher","first-page":"E91","DOI":"10.1046\/j.1440-1746.2000.02108.x","volume":"15 Suppl","author":"JH Kao","year":"2000","unstructured":"Kao J. H. & Chen D. S. Transmission of hepatitis C virus in Asia: past and present perspectives. J. Gastroenterol Hepatol. 15 Suppl, E91\u201396 (2000).","journal-title":"J. Gastroenterol Hepatol."},{"key":"BFsrep09954_CR2","first-page":"27","volume":"25","author":"DS Chen","year":"1995","unstructured":"Chen D. S. Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp. 25, 27\u201332 (1995).","journal-title":"Princess Takamatsu Symp."},{"key":"BFsrep09954_CR3","doi-asserted-by":"publisher","first-page":"e70458","DOI":"10.1371\/journal.pone.0070458","volume":"8","author":"CS Hsu","year":"2013","unstructured":"Hsu C. S. et al. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One. 8, e70458 (2013).","journal-title":"PLoS One."},{"key":"BFsrep09954_CR4","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","volume":"359","author":"AM Di Bisceglie","year":"2008","unstructured":"Di Bisceglie A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl. J. Med. 359, 2429\u20132441 (2008).","journal-title":"N Engl. J. Med."},{"key":"BFsrep09954_CR5","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1053\/j.gastro.2011.03.010","volume":"140","author":"J Bruix","year":"2011","unstructured":"Bruix J. et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 140, 1990\u20131999 (2011).","journal-title":"Gastroenterology"},{"key":"BFsrep09954_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1056\/NEJMc1307641","volume":"369","author":"CS Hsu","year":"2013","unstructured":"Hsu C. S. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl. J. Med. 369, 678 (2013).","journal-title":"N Engl. J. Med."},{"key":"BFsrep09954_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.7326\/0003-4819-138-4-200302180-00008","volume":"138","author":"Y Shiratori","year":"2003","unstructured":"Shiratori Y. et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 138, 299\u2013306 (2003).","journal-title":"Ann. Intern. Med."},{"key":"BFsrep09954_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.7326\/0003-4819-134-10-200105150-00010","volume":"134","author":"S Kubo","year":"2001","unstructured":"Kubo S. et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Intern. Med. 134, 963\u2013967 (2001).","journal-title":"Ann. Intern. Med."},{"key":"BFsrep09954_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1053\/jhep.2000.9409","volume":"32","author":"K Ikeda","year":"2000","unstructured":"Ikeda K. et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 32, 228\u2013232 (2000).","journal-title":"Hepatology"},{"key":"BFsrep09954_CR10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/hep.21415","volume":"44","author":"V Mazzaferro","year":"2006","unstructured":"Mazzaferro V. et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 44, 1543\u20131554 (2006).","journal-title":"Hepatology"},{"key":"BFsrep09954_CR11","first-page":"529","volume":"59","author":"T Ishikawa","year":"2012","unstructured":"Ishikawa T. et al. Combination PEG-IFN a-2b\/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology. 59, 529\u2013532 (2012).","journal-title":"Hepatogastroenterology"},{"key":"BFsrep09954_CR12","first-page":"724","volume":"49","author":"S Miyaguchi","year":"2002","unstructured":"Miyaguchi S. et al. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology. 49, 724\u2013729 (2002).","journal-title":"Hepatogastroenterology"},{"key":"BFsrep09954_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D., Liberati A., Tetzlaff J. & Altman D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).","journal-title":"PLoS Med."},{"key":"BFsrep09954_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins J. P. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Bmj. 343, d5928 (2011).","journal-title":"Bmj"},{"key":"BFsrep09954_CR15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","volume":"140","author":"AS Lok","year":"2011","unstructured":"Lok A. S. et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 140, 840\u2013849 (2011).","journal-title":"Gastroenterology"},{"key":"BFsrep09954_CR16","first-page":"3216","volume":"46","author":"E Bernardinello","year":"1999","unstructured":"Bernardinello E. et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology. 46, 3216\u20133222 (1999).","journal-title":"Hepatogastroenterology"},{"key":"BFsrep09954_CR17","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/hep.510290616","volume":"29","author":"DC Valla","year":"1999","unstructured":"Valla D. C. et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 29, 1870\u20131875 (1999).","journal-title":"Hepatology"},{"key":"BFsrep09954_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","volume":"346","author":"S Nishiguchi","year":"1995","unstructured":"Nishiguchi S. et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346, 1051\u20131055 (1995).","journal-title":"Lancet"},{"key":"BFsrep09954_CR19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000082098","volume":"48","author":"S Nishiguchi","year":"2005","unstructured":"Nishiguchi S., Tamori A. & Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 48, 71\u201375 (2005).","journal-title":"Intervirology"},{"key":"BFsrep09954_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1046\/j.0007-1323.2001.02054.x","volume":"89","author":"S Kubo","year":"2002","unstructured":"Kubo S. et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br. J. Surg. 89, 418\u2013422 (2002).","journal-title":"Br. J. Surg."},{"key":"BFsrep09954_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany M. G., Strader D. B., Thomas D. L. & Seeff L. B. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 49, 1335\u20131374 (2009).","journal-title":"Hepatology"},{"key":"BFsrep09954_CR22","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878\u20131887 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep09954_CR23","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/hep.510290624","volume":"29","author":"H Yano","year":"1999","unstructured":"Yano H. et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology. 29, 1708\u20131717 (1999).","journal-title":"Hepatology"},{"key":"BFsrep09954_CR24","doi-asserted-by":"publisher","first-page":"e83195","DOI":"10.1371\/journal.pone.0083195","volume":"8","author":"H Kusano","year":"2013","unstructured":"Kusano H. et al. Pegylated interferon-alpha2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One. 8, e83195 (2013).","journal-title":"PLoS One"},{"key":"BFsrep09954_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook P. J., Berlin J. A., Gopalan R. & Matthews D. R. Publication bias in clinical research. Lancet. 337, 867\u2013872 (1991).","journal-title":"Lancet"},{"key":"BFsrep09954_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/BLO.0b013e31802c9098","volume":"455","author":"RW Wright","year":"2007","unstructured":"Wright R. W., Brand R. A., Dunn W. & Spindler K. P. How to write a systematic review. Clin. Orthop. Relat. Res. 455, 23\u201329 (2007).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"BFsrep09954_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ije\/31.1.107","volume":"31","author":"CL Vale","year":"2002","unstructured":"Vale C. L., Tierney J. F. & Stewart L. A. Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int. J. Epidemiol. 31, 107\u2013111 (2002).","journal-title":"Int. J. Epidemiol."},{"key":"BFsrep09954_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1056\/NEJMc1307641","volume":"369","author":"E Lawitz","year":"2013","unstructured":"Lawitz E. & Gane E. J. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 369, 678\u2013679 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep09954_CR29","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E. et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368, 1878\u20131887 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep09954_CR30","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson I. M. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368, 1867\u20131877 (2013).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep09954","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09954.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep09954.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T13:10:34Z","timestamp":1672924234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep09954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,22]]}},"alternative-id":["BFsrep09954"],"URL":"https:\/\/doi.org\/10.1038\/srep09954","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]},"assertion":[{"value":"6 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jia-Horng Kao: Consultant for Bristol-Myers Squibb, Gilead Sciences and Novartis; on speaker\u2019s bureau for Roche, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme and Novartis. Ding-Shinn Chen: Consultant for Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Roche and Merck Sharp & Dohme. All other authors have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9954"}}